Loading...
Loading...
MESO| Name | Value |
|---|---|
| Revenues | 1,694.0K |
| Cost of Revenue | 9,696.5K |
| Gross Profit | -8,002.5K |
| Operating Expense | 3,218.5K |
| Operating I/L | -13,292.0K |
| Other Income/Expense | -3,028.5K |
| Interest Income | 5,099.5K |
| Pretax | -16,320.5K |
| Income Tax Expense | 51.0K |
| Net Income/Loss | -16,269.5K |
Mesoblast Limited is a biopharmaceutical company that develops and commercializes allogeneic cellular medicines in various therapeutic areas including cardiovascular, orthopedic disorders, oncology, hematology, and immune-mediated diseases. The company's proprietary regenerative medicine technology platform is based on specialized mesenchymal lineage cells. Its products under Phase III clinical trials include treatments for acute graft versus host disease, acute respiratory distress syndrome due to COVID-19, chronic heart failure, and chronic low back pain. Mesoblast has strategic partnerships to develop and commercialize cell therapies for various conditions, including heart failure, wound healing, and chronic low back pain.
